PolyPid Ltd. (NASDAQ:PYPD - Free Report) - Investment analysts at HC Wainwright raised their FY2029 earnings per share estimates for shares of PolyPid in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.87 for the year, up from their previous forecast of $0.75. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for PolyPid's current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for PolyPid's FY2030 earnings at $1.65 EPS.
PolyPid (NASDAQ:PYPD - Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.91 by ($1.15). The company had revenue of $30.00 million during the quarter, compared to analyst estimates of $30.00 million.
Other equities analysts have also issued reports about the company. Oppenheimer assumed coverage on PolyPid in a research report on Tuesday, October 27th. They set an "outperform" rating and a $10.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of PolyPid in a research report on Friday, September 18th. Craig Hallum set a $12.00 price objective on shares of PolyPid in a research note on Wednesday, July 22nd. Finally, Wall Street Zen raised shares of PolyPid from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $11.67.
Check Out Our Latest Report on PYPD
PolyPid Trading Down 3.0%
NASDAQ:PYPD opened at $6.40 on Friday. PolyPid has a 1-year low of $3.50 and a 1-year high of $7.15. The firm has a market capitalization of $122.11 million, a price-to-earnings ratio of -4.74 and a beta of 1.43. The business's 50-day moving average price is $5.35 and its two-hundred day moving average price is $4.79.
Institutional Trading of PolyPid
Hedge funds have recently added to or reduced their stakes in the business. HighTower Advisors LLC lifted its holdings in PolyPid by 18.2% during the third quarter. HighTower Advisors LLC now owns 13,000 shares of the company's stock worth $69,000 after acquiring an additional 2,000 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in shares of PolyPid by 32.7% in the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company's stock worth $106,000 after acquiring an additional 4,955 shares in the last quarter. AXQ Capital LP bought a new stake in shares of PolyPid in the second quarter worth about $87,000. Renaissance Technologies LLC acquired a new stake in shares of PolyPid during the first quarter worth about $81,000. Finally, Connective Capital Management LLC acquired a new stake in shares of PolyPid during the second quarter worth about $343,000. Institutional investors and hedge funds own 26.47% of the company's stock.
Top PolyPid Stories
Investors following PYPD have been watching these stories:
- Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $13 price target, implying substantial upside from the $6.40 reference price. HC Wainwright ratings
- Positive Sentiment: Commercial preparations include partner Azurity’s network of more than 1,700 U.S. hospitals. PolyPid also received a $15 million milestone payment from Azurity in October. Key takeaways for long-term investors
- Negative Sentiment: PolyPid reported Q3 2026 EPS of negative $0.24, missing the cited consensus estimate by $1.15. The earnings shortfall is a potential headwind, although investor focus may also center on the upcoming FDA decision. PolyPid quarterly earnings report
About PolyPid
(
Get Free Report)
PolyPid Ltd. NASDAQ: PYPD is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company's technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure. PolyPid's lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company's proprietary PLEX polymeric matrix. It is being developed for the prevention of surgical-site infections, initially in patients undergoing colorectal surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PolyPid, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PolyPid wasn't on the list.
While PolyPid currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
